Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting
Belite Bio (NASDAQ: BLTE) announced two upcoming poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Salt Lake City, Utah, from May 4-8, 2025.
The presentations will focus on the company's ongoing clinical trials for Stargardt disease:
- The first poster will present baseline characteristics from the Phase 3 DRAGON trial of Tinlarebant in adolescent patients, presented by Dr. Ruifang Sui
- The second poster will discuss pharmacokinetic and pharmacodynamic properties from the DRAGON II trial in Japanese adolescent patients, presented by Dr. Kaoru Fujinami
Both presentations are scheduled for Monday, May 5, from 8:30-10:15 a.m. MDT in Session 215: Retinitis Pigmentosa and IRD I.
Belite Bio (NASDAQ: BLTE) ha annunciato due prossime presentazioni in formato poster durante il Meeting Annuale dell'Association for Research in Vision and Ophthalmology (ARVO), che si terrà a Salt Lake City, Utah, dal 4 all'8 maggio 2025.
Le presentazioni si concentreranno sugli studi clinici in corso dell'azienda per la malattia di Stargardt:
- Il primo poster illustrerà le caratteristiche basali dello studio di Fase 3 DRAGON su Tinlarebant in pazienti adolescenti, presentato dalla Dott.ssa Ruifang Sui
- Il secondo poster tratterà le proprietà farmacocinetiche e farmacodinamiche dello studio DRAGON II su adolescenti giapponesi, presentato dal Dott. Kaoru Fujinami
Entrambe le presentazioni sono programmate per lunedì 5 maggio, dalle 8:30 alle 10:15 MDT, nella Sessione 215: Retinite Pigmentosa e IRD I.
Belite Bio (NASDAQ: BLTE) anunció dos próximas presentaciones en formato póster durante la Reunión Anual de la Association for Research in Vision and Ophthalmology (ARVO), que se llevará a cabo en Salt Lake City, Utah, del 4 al 8 de mayo de 2025.
Las presentaciones se centrarán en los ensayos clínicos en curso de la compañía para la enfermedad de Stargardt:
- El primer póster mostrará las características basales del ensayo de Fase 3 DRAGON con Tinlarebant en pacientes adolescentes, presentado por la Dra. Ruifang Sui
- El segundo póster abordará las propiedades farmacocinéticas y farmacodinámicas del ensayo DRAGON II en adolescentes japoneses, presentado por el Dr. Kaoru Fujinami
Ambas presentaciones están programadas para el lunes 5 de mayo, de 8:30 a 10:15 a.m. MDT, en la Sesión 215: Retinitis Pigmentosa e IRD I.
Belite Bio (NASDAQ: BLTE)는 2025년 5월 4일부터 8일까지 유타주 솔트레이크시티에서 열리는 시력 및 안과 연구 협회(ARVO) 연례 회의에서 두 건의 포스터 발표를 예정하고 있다고 발표했습니다.
발표는 회사의 진행 중인 스타가르트병 임상시험에 초점을 맞춥니다:
- 첫 번째 포스터는 청소년 환자를 대상으로 한 Tinlarebant의 3상 DRAGON 시험의 기초 특성을 루이팡 수이 박사가 발표합니다
- 두 번째 포스터는 일본 청소년 환자를 대상으로 한 DRAGON II 시험의 약동학 및 약력학 특성을 후지노미 카오루 박사가 발표합니다
두 발표 모두 5월 5일 월요일 오전 8시 30분부터 10시 15분까지 MDT 시간에 세션 215: 망막색소변성 및 IRD I에서 진행될 예정입니다.
Belite Bio (NASDAQ : BLTE) a annoncé deux prochaines présentations sous forme de posters lors de la réunion annuelle de l'Association for Research in Vision and Ophthalmology (ARVO), qui se tiendra à Salt Lake City, Utah, du 4 au 8 mai 2025.
Les présentations porteront sur les essais cliniques en cours de la société concernant la maladie de Stargardt :
- Le premier poster présentera les caractéristiques de base de l'essai de phase 3 DRAGON de Tinlarebant chez des patients adolescents, présenté par le Dr Ruifang Sui
- Le second poster abordera les propriétés pharmacocinétiques et pharmacodynamiques de l'essai DRAGON II chez des adolescents japonais, présenté par le Dr Kaoru Fujinami
Les deux présentations sont prévues le lundi 5 mai, de 8h30 à 10h15 MDT, lors de la session 215 : Rétinite pigmentaire et IRD I.
Belite Bio (NASDAQ: BLTE) kündigte zwei bevorstehende Posterpräsentationen auf dem Jahrestreffen der Association for Research in Vision and Ophthalmology (ARVO) an, das vom 4. bis 8. Mai 2025 in Salt Lake City, Utah, stattfindet.
Die Präsentationen konzentrieren sich auf die laufenden klinischen Studien des Unternehmens zur Stargardt-Krankheit:
- Das erste Poster stellt die Ausgangscharakteristika der Phase-3-Studie DRAGON von Tinlarebant bei jugendlichen Patienten vor, präsentiert von Dr. Ruifang Sui
- Das zweite Poster behandelt die pharmakokinetischen und pharmakodynamischen Eigenschaften der DRAGON II-Studie bei japanischen Jugendlichen, präsentiert von Dr. Kaoru Fujinami
Beide Präsentationen sind für Montag, den 5. Mai, von 8:30 bis 10:15 Uhr MDT in Sitzung 215: Retinitis Pigmentosa und IRD I geplant.
- Phase 3 DRAGON trial ongoing for Tinlarebant in Stargardt disease demonstrates advancement in late-stage clinical development
- Geographic expansion with DRAGON II trial including Japanese patients shows international market potential
- Multiple clinical data presentations at major industry conference (ARVO) indicates scientific validation and progress
- None.
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will give two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 4–8, 2025, in Salt Lake City, Utah. The presentations will highlight baseline patient characteristics from the ongoing DRAGON trial and pharmacokinetic and pharmacodynamic properties from the ongoing DRAGON II trial, both in Stargardt disease.
Poster Presentations:
Title: Baseline Characteristics of Adolescent Stargardt Disease Subjects Participating in a Phase 3 Study of Tinlarebant (DRAGON Trial)
Presenting Author: Dr. Ruifang Sui
Presentation Number: 1463
Session Number: 215
Session Title: Retinitis Pigmentosa and IRD I
Session Date/Time: Monday, May 5, 8:30-10:15 a.m. MDT
Title: Pharmacokinetic and Pharmacodynamic Properties of an Oral Investigational Treatment for Stargardt Disease in Adolescent Japanese Patients
Presenting Author: Dr. Kaoru Fujinami
Presentation Number: 1431
Session Number: 215
Session Title: Retinitis Pigmentosa and IRD I
Session Date/Time: Monday, May 5, 8:30-10:15 a.m. MDT
About Tinlarebant (a/k/a LBS-008)
Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in Stargardt Disease type 1 (STGD1) and also contribute to disease progression in geographic atrophy, or advanced dry age-related macular degeneration (AMD). Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, Tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the U.S., Orphan Drug Designation in the U.S., Europe, and Japan, and Sakigake Designation in Japan for the treatment of STGD1.
Stargardt Disease (STGD1)
STGD1 is the most common inherited macular dystrophy (causing blurring or loss of central vision) in both adults and children. The disease is caused by mutations in a retina-specific gene (ABCA4), which results in progressive accumulation of bisretinoids leading to retinal cell death and progressive loss of central vision. The fluorescent properties of bisretinoids and the development of retinal imaging systems have helped ophthalmologists identify and monitor disease progression. Currently, there are no FDA approved treatments for STGD1. Importantly, the appearance of bisretinoids, followed by retinal cell death, and progressive loss of vision is also observed in geographic atrophy (GA) patients. Therefore, Belite Bio is evaluating safety and efficacy of Tinlarebant in GA patients in a 2-year Phase 3 study (PHOENIX).
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
What will Belite Bio (BLTE) present at ARVO 2025 Annual Meeting?
When and where is Belite Bio's ARVO 2025 presentation scheduled?
What is the focus of Belite Bio's DRAGON trial presentation?
What research is Belite Bio presenting about Japanese patients?
What disease treatments is Belite Bio (BLTE) researching?
